Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas

Journal of Endocrinological Investigation

Volumn 27, Issue 10, 2004, Pages 937-942

  Filopanti, M ^a   Ballare E ^a   Lania, A G ^a   Bondioni, S ^a   Verga, U ^a   Locatelli, M ^a   Zavanone, L M ^a   Losa, M ^b   Gelmini, S ^c   Peri, A ^c   Orlando, C ^c   Beck Peccoz, P ^a   Spada, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Loss of heterozygosity; Somatotroph adenomas; SS receptor; sst5; Thyrotroph adenomas

Indexed keywords

CELL DNA; GROWTH HORMONE; LEUCINE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 5; THYROTROPIN;

ARTICLE; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE IDENTIFICATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HYPOPHYSIS ADENOMA; LEUKOCYTE; PHENOTYPE; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CELL; TELOMERE; TUMOR CELL;

EID: 19944429893     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347536     Document Type: Article

References (28)

1. Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994, 78: 398-403.
2. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibansky A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995, 80: 1386-92.
3. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 1995, 56: 333-42.
4. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12: 450-82.
5. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992, 89: 251-55.
6. Raynor K, Murphy WA, Coly DH, et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity of linear peptides. Mol Pharmacol 1993, 43: 838-44.
7. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jacuet F, Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsα, Pit-1, Gi2α, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999, 84: 2759-65.
8. Jaquet P, Saveanu A, Gunz G, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000, 85: 781-92.
9. Petersen S, Heyens M, Lüdecke DK, Beil FU, Schulte HM. Absence of somatostatin receptor type 2A mutations and gip oncogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) 2000, 52: 35-42.
10. Corbetta S, Ballarè E, Mantovani G, et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001, 31: 208-14.
11. Ballarè E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001, 86: 3809-14.
12. Ross DS, Downing MF, Chin WW, Keiffer JD, Ridgway EC. Divergent changes in murine pituitary concentration of free alpha and thyrotropin beta-subunits in hypothyroidism and after thyroxine administration. Endocrinology 1983, 112: 187-93.
13. Lames RA, Sarapura VD, Bruns C, et al. Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor. Endocrinology 1997, 138: 719-24.
14. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WE, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors. Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995, 55: 644-6.
15. Bates AS, Farrel WE, Bicknell EJ, et al. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997, 82: 818-24.
16. Simpson DJ, Magnay J, Bicknell JE, et al. Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) despite loss of RB1 product in somatotropinomas. Cancer Res 1999, 59: 1562-6.
17. Asa SL, Ezzat S. The pathogenesis of pituitary tumors. Nat Rev Cancer 2002, 2: 836-49.
18. Nyegaard M, Borglum AD, Bruun TG, et al. Novel polymorphisms in the somatostatin receptor 5 (SSTR5) gene associated with bipolar affective disorder. Mol Psych 2002, 7: 745-54.
19. Giustina A, Melmed S. Acromegaly consensus: the next steps. J Clin Endocrinol Metab 2003, 88: 1913-4.
20. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996, 17: 610-38.
21. Ballarè E, Mantovani S, Lania A, Di Blasio AM, Vallar L, Spada A. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors. J Clin Endocrinol Metab 1998, 83: 4386-90.
22. Farrel WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 2000, 21: 174-98.
23. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24: 28-47.
24. Huizenga NAT, DeLange P, Koper JW, et al. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab 1998, 83: 917-21.
25. Sharma K, Patel YC, Srikant CB. C-terminal region of the human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol 1999, 13: 82-92.
26. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptor for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288: 154-7.
27. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003, 148: 433-42.
28. Clayton RN, Pfeifer M, Atkinson AB, et al. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 2000, 6: 3973-82.